Abstract
Successful treatment of neuroendocrine tumor disease of the gastroenteropancreatic system requires a multimodal approach. Radical tumor surgery is required before other therapies are initiated. So far, only surgery has proven to be curative. If surgical intervention is not possible or a tumor-free state cannot be achieved, biotherapy with the somatostatin analogues octreotide or lanreotide should then be preferably carried out in patients with functional tumors. Interferon-α can alternatively be given. In patients with gastrinoma, therapy with proton pump inhibitors (e.g., omeprazol) is the initial treatment of choice. In patients with nonfunctional tumors, indication for treatment is only given in cases of documented tumor progress.
In case of progressive tumor disease or functionality under the above-mentioned therapies, treatment with somatostatin analogues can be intensified by dose escalation or alternatively by a combination therapy with interferon-α and a somatostatin analogue. On the basis of the less favorable response of neuroendocrine foregut tumors to biotherapy, chemotherapy should be initiated after failure of biotherapy in documented tumor progression. A combination of streptozotocin and 5-fluorouracil, possibly combined with D,L-folinic acid, is the treatment of choice, considering the response and side effect rates. In case of predominantly anaplastic neuroendocrine tumors in advanced stages, good tumor response rates with a chemotherapeutic scheme consisting of cisplatin and etoposide can be achieved. Since the chemotherapy scheme is less effective in patients with midgut or hindgut tumors, chemoembolization of liver metastases should follow biotherapy. The response to chemoembolization may be increased by simultaneous systemic chemotherapy. Attention should always be paid to an adequate analgesic drug administration.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Ahlman H, Wängberg B, Tisell LE, Nilsson O, Fjälling M, Forsell-Aronsson E (1994) Clinical efficacy of octreotide scintigraphy in patients with midgut carcinoid tumours and evaluation of intraoperative scintillation detection. Br J Surg 81: 1144–1149
Anthony L, Johnson D, Hande K (1993) Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 32: 217–223
Arnold R, Neuhaus C, Benning R, Schwerk W, Trautmann ME (1993) Somatostatin analog Sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors, World J Surg 17: 511–519
Balkwill FR (1989) Interferons. Lancet 1: 1060–1063
Bartsch HH, Stockman F, Arnold R, Creutzfeldt W (1990) Treatment of patients with metastatic carcinoid tumors by recombinant human interferon-alpha: results from a phase II study. J Cancer Res Clin Oncol 116: 305
Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S (1986) The carcinoid syndrome: palliation by hepatic artery embolization. Am J Rad 147: 149–154
Creutzfeld W, Bartsch HH, Jacubaschke K, Stöckmann F (1991) Treatment of gastrointestinal endocrine tumors with alpha-interferon and octreotide. Acta Oncol 30: 529–535
Dingerkus H, Völler H, Schröder K, Dißmann R, Henning L, Agrawal R, Linderer T, Wiedenmann B (1994) Endokardfibrose bei neuroendokrinen Tumoren des gastroenteropankreatischen Systems. Dtsch Med Wochenschr 119: 647–652
Engström PF, Lawin PT, Moertel CG, Fölsch E, Douglass HO (1984) Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumors. J Clin Oncol 2: 1255–1259
Eriksson B, Skogseid B, Lundqvist G, Wide L, Wilander E, ()berg K (1990) Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 65: 1883–1890
Eriksson B, Öberg K (1993) An update of medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 32: 203–208
Frohlich JC, Bloomgarden ZT, Oates JA, McGugan J, Rabinowitz D (1978) The carcinoid flush: provocation by pentagastrin and inhibition by somatostatin. N Engl J Med 299: 1055–1057
Hanssen LE, Schrumpf E, Kolbenstvedt AN, Tausjö J, Dolva LO (1989) Treatment of malignant metastatic midgut carcinoid tumours with recombinant human alpha-2binterferon with or without prior hepatic artery embolization. Scand J Gastroenterol 24: 787–795
Heron I, Thomas F, Dero M (1993) Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analogue BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 76: 721–727
Joensuu H, Katka K, Kujari H (1992) Dramatic response of a metastatic carcinoid tumor to a combination of interferon and octreotide. Acta Endocrinol (Copenh) 126: 184–185
John M, Meyerhof W, Richter D, Waser B, Schaer JC, Boese-Landgraf J, Neuhaus P, Scherübl H, Riecken E-O, Reubi JC, Wiedenmann B (1996) Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut 38 (in press)
Kvols LK, Moertel CG, O’Connell MJ, Schutt AK, Rubin J, Hahn RG (1986) Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 315: 663–666
Kvols LK (1989) Therapy of malignant carcinoid syndrome. Endocrinol Metabol Clin North Am 18: 557–568
Marlink RG, Lokich T, Robins JR, Clouse ME (1990) Hepatic arterial embolization for metastatic hormone-secreting tumor: technique, effectivness, and complications. Cancer 65: 2227–2232
Moertel CG (1987) An odyssey in the land of small tumors. J Clin Oncol 5: 1502–1522
Moertel CG, Hanley JA, Johnson LA (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303: 1189–1194
Moertel CG, Kvols LK, O’Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Cancer 68: 227–232
Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozocindoxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326: 519–523
Moertel CG, Johnson CM, McKusick MA, Martin JK, Nagorney DM, Kvols LK, Rubin J, Kunselman S (1994) The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 120: 302–309
Nold R, Frank M, Kajdan U, Trost U, Klose KJ, Arnold R (1994) Kombinierte Behandlung metastasierter neuroendokriner Tumoren des Gastrointestinaltrakts mit Octreotid und Interferon-Alpha. Z Gastroenterol 32: 193–197
Norheim I, Öberg K, Theodorsson Norheim, E, Lindgren PG, Lundin I, Lundqvist G, Magnusson A, Wide L, Wilander E (1987) Malignant carcinoid tumors: an analysis of 103 patients with regard to tumor localization, hormone production and survivgal. Ann Surg 206: 115–125
Öberg K (1993) Chemotherapy and biotherapy in neuroendocrine tumors. Curr Opin Oncol 5: 110–120
Öberg K, Eriksson, B (1991) The role of interferons in the mangement of carcinoid tumors. Acta Oncol 30: 519–522
Öberg K, Funa K, Alm G (1983) Effects of leucocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 309: 129–133
Öberg K, Norheim I, Lind E, Alm G, Lundquist G, Wide L, Jonsdottir B, Magnusson A, Wilander E (1986) Treatment of malignant carcinoid tumors with human leucocyte interferon: long-term results. Cancer Treat Rep 11: 1297–1304
Öberg K, Norheim I, Theodorsson E (1991) Treatment of malignant midgut carcinoid tumors with the long-acting somatostatin-analogue, octreotide. Acta Oncol 30: 503–507
Scherübl H, Hescheler J, Bychkov R, Cuber JC, John M, Riecken EO, Wiedenmann B (1994a) Elecrical activity and calcium channels in neuroendocrine cells. Ann NY Acad Sci 733: 335–339
Scherübl H, Wiedenmann B, Riecken E-O, Faiss S, Thomas F, Kommerell B, Räth U (1994b) Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide. Eur J Cancer 6: 1590–1591
Skogseid B, Eriksson B, Lundqvist G, Lörelius LE, Rastad J, Wide L, Wilander E, Akerström G, ()berg K (1991) Multiple endocrine neoplasia type 1: a ten-year prospective screening study in four kindreds. J Clin Endocrinol Metab 73: 281–287
Smith DB, Scarffe JH, Wagstaff J, Johnston RJ (1987) Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor. Cancer Treat Rep 7: 1265–1268
Stöckmann F, Creutzfeld W (1988) Behandlung gastrointestinaler neuroendockriner Tumoren mit dem Somatostatin-Analog Octreotide (Sandostatin). Z Gastroenterol 26: 665
Tiensuu Janson EM, Ahlström H, Andersson T, Öberg K (1992) Octreotide and interferon alfa; a new combination for the treatment of malignant carcinoid tumors. Eur J Cancer 28A: 1647–1650
Todisco A, Seva C, Takeuchi Y, Dickinson CJ, Yamada T (1994) Inhibition of AP-1 function via SSTR2 mediates somatostatin inhibition of cell proliferation. Dig Dis Sci 8: 1788
Vinik AI, Thompson N, Echkauser F, Mottari AR (1989) Clinical features of carcinoid syndrome and the use of somatostatin analogue and its management. Acta Oncol 28: 389–402
Wiedenmann B, Räth U, Rädsch R, Becker F, Kommerell B (1988) Tumor regression of an ileal carcinoid under the treatment with the somatostatin analogue SMS 201995. Klin Wochenschr 6: 75–77
Yamada Y, Reisine T, Law SF, Ihara Y, Kubota A, Kagimoto S, Seino M, Seino Y, Bell GI, Seino S (1992) Somatostatin receptors, an expanding gene family: cloning and functional characterization of human sstr 3, a protein coupled to adenylyl cyclase. Mol Endocrinol 6: 2136–2142
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Faiss, S., Scherübl, H., Riecken, E.O., Wiedenmann, B. (1996). Drug Therapy in Metastatic Neuroendocrine Tumors of the Gastroenteropancreatic System. In: Kreuser, ED., Schlag, P.M. (eds) New Perspectives in Molecular and Clinical Management of Gastrointestinal Tumors. Recent Results in Cancer Research, vol 142. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-80035-1_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-80035-1_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-80037-5
Online ISBN: 978-3-642-80035-1
eBook Packages: Springer Book Archive